Browsing by Author "Guerra, C"
Now showing 1 - 9 of 9
Results Per Page
Sort Options
- Avaliação da eficácia terapêutica do ceftriaxone versus piperacilina na profilaxia da infecção pós-histerectomiaPublication . Paulo, AS; Marta, J; Guerra, C; Tavares, M; Leitão, F; Riscado, I; Raimundo, D; Dias, MF; Ngan-Va, L; Oliveira, CF
- Avaliação dos resultados da biópsia do gânglio sentinela no carcinoma da mamaPublication . Saleiro, S; Rodrigues, AC; Frutuoso, C; Guerra, C; Coimbra, C; Amaral, N; Oliveira, CF
- Carcinoma espinho-celular do colo do útero tipo linfoepitelioma-likePublication . Pires, MA; Andrade, MJ; Guerra, C; Silva, T; Oliveira, CF; Matos-Beja, ALymphoepithelioma-like carcinomas of the cervix uteri are very rare. They are poorly differentiated squamous cell carcinomas with intense stromal lymphocytic infiltration. These histologic features are similar to nasopharyngeal lymphoepithelioma and may have a better prognosis than other tumors of the cervix. A lymphoepithelioma-like lesion of the cervix uteri is described in a 33-year-old Caucasian woman who had an episode of vaginal bleeding. A review of the literature about these types of tumor is also presented.
- Carcinoma misto do ovário: a propósito de um caso clínicoPublication . Franco, S; Andrade, MJ; Cortesão, P; Carvalho, G; Sousa, R; Guerra, C; Silva, T; Oliveira, CF
- Comparação da eficácia da piperacilina versus cefazolina na profilaxia da infecção pós-histerectomiaPublication . Moreira, C; Gomes, C; Nobre, C; Frutuoso, C; Guerra, C; Marques, C; Marta, J; Oliveira, CF
- Efeitos secundários da castração com goserelina em mulheres com cancro da mamaPublication . Franco, S; Lapa, P; Guerra, C; Pereira, L; Oliveira, CFIn the last few years, ovarian ablation with GnRH agonists has been used as first-line adjuvant therapy in pre and perimenopausal breast cancer. These drugs suppress ovarian function in the hypothalamic-pituitary axis and they have adverse effects in other end-organs. A retrospective study was conducted on 35 premenopausal women, with breast cancer, and treated with goserelin, in order to investigate the effects of iatrogenic estrogen suppression. All women complaint of amenorrhea and only half of them referred hot-flashes, weight gain or arthralgias. Hot-flushes and arthralgias remit spontaneously in the end of the treatment. Osteodensitometry was used to access bone mass. There was a reduction in mineral bone mass and T-score at femoral neck and lumbar spine after the treatment with goserelin, but without statistical significance, except for the T-score in lumbar spine.
- Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patientsPublication . Silva, HA; Abraúl, E; Raimundo, D; Dias, MF; Marques, C; Guerra, C; Oliveira, CF; Regateiro, FJ;The aim of this study is to evaluate epidermal growth factor receptor variant III, EGFRvIII, a cancer specific mutant, as a possible marker for the diagnosis of breast cancer occult systemic disease. EGFRvIII mRNA was identified by an RT-nested PCR with a high sensitivity. In 102 women studied, the mutant was detected in the peripheral blood of 30% of 33 low risk, early stage patients, in 56% of 18 patients selected for neoadjuvant chemotherapy, in 63.6% of 11 patients with disseminated disease and 0% of 40 control women. In low risk, early stage patients, the presence of one or more tumour characteristics predicting recurrence such as the absence of oestrogen receptors and the presence of ERBB2 or histologic grades G2/G3 was significantly associated with EFGRvIII detection (p<0.05). EGFRvIII mRNA has characteristics to be a useful marker for the diagnosis of occult systemic disease in breast cancer. Follow-up studies will evaluate its clinical value as a decision criterion for systemic therapy.
- Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group).Publication . Witteveen, PO; van der Velden, J; Vergote, I; Guerra, C; Scarabeli, C; Demonty, G; Reed, NBACKGROUND: No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment. PATIENTS AND METHODS: In this phase II study, patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to 10 cycles. Primary objective was response rate. Secondary objectives were response duration and toxicity. Response evaluation was assessed by World Health Organisation criteria, toxicity according to Common Toxicity Criteria. RESULTS: Thirty-one women from 10 institutions were included, with a median age of 64 (range 47-84), of which 29 were assessable for response. On study patients received a median of four cycles (range 1-10). Safety: Grade 3 and 4 neutropenia was seen in eight patients (8/29 = 27.6%), which in one patient resulted in neutropenic fever and treatment-related death. Further treatment-related grade 3/4 toxicity includes fatigue in three patients (10.3%) and neuropathy in one patient (3.4%). Efficacy: Overall response was 13.8% (n = 4; two complete responses + two partial responses). With a median follow-up of 24 months, median PFS was 2.6 months (95%confidence interval 2.04-4.21). CONCLUSION: Paclitaxel shows moderate activity for local control in advanced vulvar cancer.
- Tumor uterino semelhante ao tumor dos cordões sexuais do ovárioPublication . Franco, S; Andrade, MJ; Silva, T; Guerra, C; Oliveira, CFUterine tumors resembling ovarian sex-cord tumors are rare and few cases are published in the literature. The authors describe a recently diagnosed one. The clinical features consisted of: abnormal vaginal bleeding and enlargement of the uterus, which allowed confusion with several types of uterine pathology: benign or malignant one; the diagnosis is exclusively histopathological. These tumors have a benign biological behaviour.